| --- | --- | --- | --- | |-------|-------|---------------------|-----------------------------------------------------------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Developing Regenerative Therapies that Reverse Chronic Disease | | | | David J. Mazzo, PhD | | | | | | President and Chief Executive Officer | September 15, 2020 | Nasdaq: CLBS Forward-looking statement 2 This Investor Presentation contains forward-looking statements within the meaning of th ...

Caladrius Biosciences, Inc. (CLBS) Q2 2020 Earnings Conference Call August 13, 2020 4:30 PM ET Company Participants John Menditto – Vice President, Investor Relations and Corporate Communications David Mazzo – President and Chief Executive Officer Conference Call Participants Kumar Raja – Brookline Capital Management Joe Pantginis – H.C. Wainwright Operator Welcome to the Caladrius Bioscience Second Quarter 2020 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delawa ...

| --- | --- | --- | |-------|-------|---------------------------------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Dedicated to Developing Therapies | | | | that Reverse Ischemic Disease | | | | David J. Mazzo, PhD | | | | President and Chief Executive Officer | May 7, 2020 | Nasdaq: CLBS Forward-looking statement 2 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-lookin ...

Caladrius Biosciences, Inc. (CLBS) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO & Director Joseph Talamo - CFO & SVP Douglas Losordo - EVP, Global Head, R&D & Chief Medical Officer Conference Call Participants Emanuela Branchetti - H.C. Wainwright & Co. Peter Enderlin - MAZ Capital Advisors Operator Hello, and welcome to the Caladrius Biosciences First Quarter 2020 Financial Results and Business Up ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) DELAWARE 22-2343568 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ...

Caladrius Biosciences, Inc. (CLBS) Q4 2019 Earnings Conference Call March 5, 2020 4:30 PM ET Company Participants John Menditto - Vice President of Investor Relations & Corporate Communications David Mazzo - President & Chief Executive Officer Joseph Talamo - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Jason Kolbert - Dawson James Steve Brozak - WBB Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Bioscience Fourth Quarter and Full Year 2019 Financial R ...

| --- | --- | --- | |-------|-------|---------------------------------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Advancing Restorative Therapies | | | | to Treat Ischemic Disease | | | | David J. Mazzo, PhD | | | | President and Chief Executive Officer | March 5, 2020 | Nasdaq: CLBS Forward-looking statement 2 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 CALADRIUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) ...

| --- | --- | |-------|---------------------------------------| | | | | | | | | | | | | | | | | | | | | Advancing Restorative Therapies | | | to Treat Ischemic Disease | | | David J. Mazzo, PhD | | | President and Chief Executive Officer | Februar y 5, 2020 | Nasdaq: CLBS Forward-looking statement 2 This Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as ...